Review
Biochemistry & Molecular Biology
Jorge Melendez-Zajgla, Vilma Maldonado
Summary: This review summarizes the current knowledge about the positive and negative effects of lncRNAs in the stemness phenotype of pancreatic ductal adenocarcinoma cancer (PDAC).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Hao Yuan, Jinhui Liu, Li Zhao, Pengfei Wu, Guosheng Chen, Qun Chen, Peng Shen, Taoyue Yang, Shaoqing Fan, Bin Xiao, Kuirong Jiang
Summary: Through analysis of clinical information and genetic transcriptome data of PDAC patients, a m5C-related lncRNA prognostic risk model was established and its relationship with PDAC immune microenvironment was studied. The risk model showed predictive ability and could potentially serve as a therapeutic target for PDAC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xiaoyang Lan, Gabrielle Robin, Jessica Kasnik, Grace Wong, Omar Abdel-Rahman
Summary: Pancreatic ductal carcinomas (PDACs) are difficult to diagnose early and have a poor prognosis. Many PDAC patients suffer from nutritional deficiencies related to their cancer. Pancreatic enzyme insufficiency (PEI) is a common cause of malnutrition in PDAC. This paper reviews past studies on malnutrition in PDAC, focusing on PEI and its treatment, and highlights knowledge gaps among healthcare professionals regarding PEI.
Article
Radiology, Nuclear Medicine & Medical Imaging
Seyoun Park, Jonathan G. Sham, Satomi Kawamoto, Alex B. Blair, Noah Rozich, Daniel F. Fouladi, Shahab Shayesteh, Ralph H. Hruban, Jin He, Christopher L. Wolfgang, Alan L. Yuille, Elliot K. Fishman, Linda C. Chu
Summary: This study found that adding CT radiomics features to standard clinical factors improves survival prediction in patients with PDAC. The most relevant radiomics features were selected through feature reduction, showing increased accuracy in classifying high-risk versus low-risk groups.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2021)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Ailin Wei, Huiling Zhao, Xue Cong, Linyao Wang, Yiyang Chen, Juxiang Gou, Ziyi Hu, Xiuying Hu, Yali Tian, Ka Li, Yufeng Deng, Haojiang Zuo, Mei Rosemary Fu
Summary: This study investigated the association between oral mycobiota and pancreatic ductal adenocarcinoma (PDAC). The findings suggest that PDAC patients have increased fungal abundance and decreased fungal diversity compared to healthy controls. Certain fungal species, such as Aspergillus and Cladosporium, showed high classification powers in distinguishing PDAC patients from healthy controls. The findings highlight the potential of using oral mycobiota as a biomarker for early detection and prevention of PDAC.
Review
Medicine, General & Internal
Natalia Michalak, Ewa Malecka-Wojciesko
Summary: This study summarizes the known modifiable risk factors for pancreatic ductal adenocarcinoma (PDAC) as well as recent reports. PDAC has a late diagnosis and poor prognosis, making accurate analysis of risk factors crucial. The incidence of PDAC is increasing, with the lowest five-year survival rate among all tumors. The impact of cigarette smoking, alcohol consumption, and chronic pancreatitis in increasing the risk of PDAC is continuously confirmed, while emerging reports focus on the influence of lifestyle factors and hepatotropic viruses.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Neurosciences
Bo Ni, Yiqing Yin, Zekun Li, Junjin Wang, Xiuchao Wang, Kaiyuan Wang
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with late diagnosis and therapy resistance. The peripheral nerve has been found to play an important role in tumor growth and immune escape in the tumor microenvironment. Understanding the crosstalk between the neuronal system and PDAC may provide new insights into tumor progression and potential therapeutic targets.
NEUROSCIENCE BULLETIN
(2023)
Article
Reproductive Biology
Bei-Bei Zhang, Meng-Xiao Li, Hong-Na Wang, Chao Liu, Yan-Yan Sun, Teng-He Ma
Summary: In this study, the expression of lncRNAs and mRNAs associated with ovarian follicle development in Taihang chickens was analyzed at the genome-wide level. The findings identified key pathways and regulatory factors related to follicle selection, providing a new foundation for future research on reproductive physiology in Taihang chickens and offering new opportunities to improve their laying performance.
Article
Oncology
Da Qin, Yu Zhao, Qingdong Guo, Shengtao Zhu, Shutian Zhang, Li Min
Summary: The study proposed a RNA ratio-based algorithm to quantify EVs-derived RNAs in PDAC and developed a promising prediction model that could effectively differentiate PDAC patients from noncancerous controls.
Review
Pharmacology & Pharmacy
Xufeng Tao, Hong Xiang, Yue Pan, Dong Shang, Junchao Guo, Ge Gao, Gary Guishan Xiao
Summary: PDAC is a highly malignant lethal disease that is caused by pancreatitis and involves various pancreatic cells interacting in an inflammation-mediated microenvironment. Understanding the players and their interactions is crucial for the development of effective therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Oncology
Shantel Angstadt, Qingfeng Zhu, Elizabeth M. Jaffee, Douglas N. Robinson, Robert A. Anders
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with low therapeutic response rates. Current treatments are ineffective due to genetic heterogeneity, early micrometastases, and an immunosuppressive tumor microenvironment. An innovative approach targeting the mechanical properties of cancer cells, specifically PDAC, can simultaneously impact multiple cancer-driving systems. Manipulation of the cell's mechanical system has shown potential for preventing metastasis and regulating oncogenic behaviors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Benli Xiao, Yuzhen Ge, Rui Zhao, Yewei Zhang, Yi Guo, Shilong Zhang, Bo Li, Peng Qiu, Zheng Chao, Shi Zuo
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited targeted therapeutic options. This study investigates the role of NAP1L5 in PDAC and its regulatory relationship with PHLPP1. The findings show that NAP1L5 is upregulated in PDAC and its knockdown suppresses cell proliferation. Mechanistically, NAP1L5 activates the AKT/mTOR signaling pathway by promoting the degradation of PHLPP1. These findings suggest that NAP1L5 could be a potential therapeutic target for PDAC.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Cell Biology
Zengyu Feng, Kexian Li, Jianyao Lou, Yulian Wu, Chenghong Peng
Summary: A novel 8-gene signature based on EMT-related genes was established to predict therapeutic response for PDAC patients, showing good performance in training and validation cohorts and associations with cancer-related pathways.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Medicine, Research & Experimental
Vida Mashayekhi, Orsola Mocellin, Marcel H. A. M. Fens, Gerard C. Krijger, Lodewijk A. A. Brosens, Sabrina Oliveira
Summary: This review discusses the challenges in the treatment and early diagnosis of pancreatic ductal adenocarcinoma (PDAC), emphasizing the need for more effective and better-tolerated treatment options. It also highlights the discovery of transmembrane proteins that are overexpressed in PDAC cells, which could potentially serve as targets for treatment and diagnosis.